Kurt R. Karst

Hyman, Phelps & McNamara (Washington DC)

Kurt Karst is a Director at Hyman, Phelps & McNamara, P.C. Mr. Karst provides regulatory counseling to pharmaceutical manufacturers concerning Hatch-Waxman patent and exclusivity issues, myriad drug development issues, pediatric testing issues, and orphan drug issues. Previously, he was a lobbyist for F. Hoffman-La Roche Inc. Mr. Karst served as an articles editor for the American University Law Review, and in 1995, was awarded a Fulbright Scholarship for post-graduate studies in Germany. He has published in the American University Law Review, the Food and Drug Law Journal and Update, RAPS FOCUS, and many other publications, and is co-author of the Food and Drug Law Institute’s Drug and Biologic Approvals: The Complete Guide for Small Businesses-FDA Financial Assistance and Incentives. Mr. Karst is a graduate of the American University Washington College of Law, and holds a Bachelor of Arts degree in political science and German from Marquette University. He is admitted to practice law in Maryland and the District of Columbia, and is a primary author of the FDA Law Blog (www.FDAlawblog.net).


256 Bulletin

Kurt R. Karst The US Court of Appeals for the Third Circuit applies the rule of reason and rejects the "scope of the patent" test when pharma patent settlement violates the antitrust laws (Schering-Plough)


In our post, “Hot Ticket Item – Patent Settlement Agreement Challenges,” we provided a round-up of the latest and greatest from ongoing litigation concerning patent settlement agreements (or “pay-for-delay” agreements if you prefer that term – we don’t). It’s only been about three weeks since that (...)

Send a message